KR20050034568A - Branched-amino acid supplement food - Google Patents
Branched-amino acid supplement food Download PDFInfo
- Publication number
- KR20050034568A KR20050034568A KR1020040103923A KR20040103923A KR20050034568A KR 20050034568 A KR20050034568 A KR 20050034568A KR 1020040103923 A KR1020040103923 A KR 1020040103923A KR 20040103923 A KR20040103923 A KR 20040103923A KR 20050034568 A KR20050034568 A KR 20050034568A
- Authority
- KR
- South Korea
- Prior art keywords
- amino acids
- amino acid
- branched chain
- player
- chain amino
- Prior art date
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 13
- 239000013589 supplement Substances 0.000 title description 5
- 150000005693 branched-chain amino acids Chemical class 0.000 claims abstract description 30
- 235000020776 essential amino acid Nutrition 0.000 claims abstract description 23
- 239000003797 essential amino acid Substances 0.000 claims abstract description 23
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 14
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 14
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 14
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940024606 amino acid Drugs 0.000 claims abstract description 14
- 150000001413 amino acids Chemical class 0.000 claims abstract description 14
- 239000004474 valine Substances 0.000 claims abstract description 14
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 13
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960000310 isoleucine Drugs 0.000 claims abstract description 13
- 235000013376 functional food Nutrition 0.000 claims abstract description 11
- 230000036541 health Effects 0.000 claims abstract description 11
- 235000005550 amino acid supplement Nutrition 0.000 claims abstract description 9
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 29
- 229960003080 taurine Drugs 0.000 claims description 14
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 10
- 229930182816 L-glutamine Natural products 0.000 claims description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 229960003284 iron Drugs 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- 229930003471 Vitamin B2 Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 229960001714 calcium phosphate Drugs 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- 229960000869 magnesium oxide Drugs 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002477 riboflavin Drugs 0.000 claims description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 235000019164 vitamin B2 Nutrition 0.000 claims description 2
- 239000011716 vitamin B2 Substances 0.000 claims description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 2
- 235000005282 vitamin D3 Nutrition 0.000 claims description 2
- 239000011647 vitamin D3 Substances 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 229940021056 vitamin d3 Drugs 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- 229960001296 zinc oxide Drugs 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 abstract description 31
- 210000004369 blood Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- 235000015278 beef Nutrition 0.000 abstract description 5
- 235000013601 eggs Nutrition 0.000 abstract description 5
- 235000013336 milk Nutrition 0.000 abstract description 5
- 239000008267 milk Substances 0.000 abstract description 5
- 210000004080 milk Anatomy 0.000 abstract description 5
- 229920002527 Glycogen Polymers 0.000 abstract description 4
- 230000015556 catabolic process Effects 0.000 abstract description 4
- 229940096919 glycogen Drugs 0.000 abstract description 4
- 235000010627 Phaseolus vulgaris Nutrition 0.000 abstract description 3
- 244000046052 Phaseolus vulgaris Species 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000009469 supplementation Effects 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 8
- 235000015872 dietary supplement Nutrition 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000000663 muscle cell Anatomy 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008934 Muscle Proteins Human genes 0.000 description 3
- 108010074084 Muscle Proteins Proteins 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 206010001497 Agitation Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- PDPXHRBRYUQCQA-SFOWXEAESA-N [(1s)-1-fluoro-2-(hydroxyamino)-2-oxoethyl]phosphonic acid Chemical compound ONC(=O)[C@@H](F)P(O)(O)=O PDPXHRBRYUQCQA-SFOWXEAESA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000008047 antioxidant nutrient Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000037257 muscle growth Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 235000021075 protein intake Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- 229960002666 1-octacosanol Drugs 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000025938 carbohydrate utilization Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000020979 dietary recommendations Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
본 발명은 본 발명은 무산소 상태에서 순간적인 임팩트 파워를 증대 시키는 필수 아미노산중 분지사슬아미노산을 이용한 건강기능식품에 관한 것으로, 보다 상세하게는 자연에서 존재하는 우유, 달걀, 콩, 쇠고기 등에 포함된 필수아미노산과 유사하도록 루이신(L), 이소루이신(I), 발린(V)등으로 구성된 분지사슬형 아미노산(이하, "LIV"라 한다)을 포함하는 무산소 상태에서 순간적인 임팩트 파워를 증대 시키는 필수 아미노산중 분지사슬아미노산을 이용한 건강기능식품에 관한 것이다.The present invention relates to a health functional food using a branched chain amino acid among essential amino acids to increase the instantaneous impact power in the anaerobic state, and more particularly, essential ingredients contained in milk, eggs, beans, beef, etc. existing in nature. Increases instantaneous impact power in an anaerobic state, including branched chain amino acids consisting of leucine (L), isoleucine (I), valine (V), and so on, similar to amino acids It relates to a health functional food using a branched chain amino acid among essential amino acids.
이러한 본 발명에 의한 분지사슬 아미노산 보충 식품을 태권도선수, 골프선수, 격투기선수, 축구선수, 야구선수, 유도선수, 레슬링선수, 배구선수, 농구선수, 축구선수 등의 운동선수들에게 섭취시키므로써, 선수들의 혈중 필수아미노산의 농도를 상승시키며, 근 글리코겐의 분해를 감소시켜 근력의 감소를 억제하는 효과가 있다.By ingesting the branched chain amino acid supplement food according to the present invention to athletes such as taekwondo player, golf player, martial arts player, football player, baseball player, judo player, wrestler, volleyball player, basketball player, soccer player, Increasing the concentration of essential amino acids in the blood of athletes, reducing the breakdown of muscle glycogen has the effect of suppressing the decrease in muscle strength.
Description
본 발명은 무산소 상태에서 순간적인 임팩트 파워를 증대 시키는 필수 아미노산중 분지사슬아미노산을 이용한 건강기능식품에 관한 것으로, 보다 상세하게는 자연에서 존재하는 우유, 달걀, 콩, 쇠고기 등에 포함된 필수아미노산과 유사하도록 루이신(L), 이소루이신(I), 발린(V)등으로 구성된 분지사슬형 아미노산(이하, "LIV"라 한다)을 포함하는 무산소 상태에서 순간적인 임팩트 파워를 증대 시키는 필수 아미노산중 분지사슬아미노산을 이용한 건강기능식품에 관한 것이다.The present invention relates to a health functional food using a branched chain amino acid among essential amino acids that increase instantaneous impact power in anoxic state, and more specifically, similar to essential amino acids contained in milk, eggs, beans, beef, etc. existing in nature. Among the essential amino acids to increase the instantaneous impact power in the anaerobic state, including branched chain amino acids (hereinafter referred to as "LIV") consisting of leucine (L), isoleucine (I), valine (V) It relates to a health functional food using a branched chain amino acid.
운동에 있어서 중요한 요인은 그 첫째가 운동을 하고자 하는 마음가짐(Mind control)이고, 둘째는 적절한 영양섭취이며, 셋째는 충분한 휴식이다. 상기와 같은 중요한 인자에서 운동을 하고자 하는 마음가짐과 충분한 휴식은 본인의 노력과 시간에 의해서 해결할 수 있으나 영양섭취는 그렇지 못하다.An important factor in exercise is firstly the mind control to exercise, the second is proper nutrition, and the third is sufficient rest. Attention to exercise and sufficient rest in the above important factors can be solved by one's own effort and time, but nutrition is not.
이에 따라, 본 발명자는 대한민국 공개특허 제10-2003-0013836호(2003.02.15공개, 출원번호 10-2001-0048037호)에 공개된 것과 같이, 분말상태의 말토덱스트린, 과당, 포도당, 단백질, 콜라겐(젤라틴), 타우린, L-글루타민, 구연산, 글루코사민, 비타민, 포사인콘드로, 동충하초, L-카르니틴, 아미노실크, 카라믹스, 구아검, 제네비아, 옥타코사놀, 치자그린, 과일향을 혼합하여 된 스포츠인용 영양보조식품을 개발하였다.Accordingly, the present inventors have disclosed powder maltodextrin, fructose, glucose, protein, collagen, as disclosed in Korean Patent Publication No. 10-2003-0013836 (published on Feb. 15, 2003, application number 10-2001-0048037). (Gelatin), taurine, L-glutamine, citric acid, glucosamine, vitamins, posa and chondroitin, Cordyceps sinensis, L-carnitine, aminosilk, caramix, guar gum, geneabia, octacosanol, gardenia green, fruit flavor A nutritional supplement for sports is developed.
그러나, 상기한 종래의 스포츠인용 영양보조식품은 오랜 시간동안 지속적으로 뛰어야 하는 마라톤이나 격렬한 운동을 하기전후에 섭취하여 체내의 에너지원 역할을 하는 각종 영양소가 포함되어 있으나, 격렬한 근 활동이 요구되는 태권도선수, 축구선수, 야구선수, 유도선수, 레슬링선수, 농구선수, 축구선수나 순간적인 근파워가 요구되는 골프선수, 배구선수, 격투기선수 등 운동선수들의 근 글리코겐의 분해를 방지할 수 있는 적절한 조성비의 분지사슬 아미노산이 포함되어 근력의 감소가 발생하지 않는 새로운 영양보조식품의 개발의 필요성이 대두되어 왔다.However, the conventional sports citation nutritional supplements contain a variety of nutrients that act as a source of energy in the body by ingesting before or after a marathon or a vigorous exercise that must be continuously run for a long time, but Taekwondo that requires intense muscle activity Proper composition ratio to prevent the breakdown of muscle glycogen by athletes, football players, baseball players, judo players, wrestlers, basketball players, soccer players or golf players, volleyball players, martial arts players who require instant muscle power There has been a need for the development of new dietary supplements containing branched chain amino acids that do not cause muscle loss.
운동선수의 열량 섭취는 운동과 동반되는 열량소비에 의하여 결정되며 영양소 필요량은 운동의 강도와 시간 및 운동의 종류에 따라 다르다. 우리나라 운동선수의 경우, 영양 권장량(RDA)은 일반인들의 1.5 ~ 2배로 남자 선수에게는 3,000~5,000 kcal/day, 여자 선수에게는 2,500 ~ 3,500 kcal/day을 권장하고 있으며, 권장량에 속한 단백질 요구량은 일반인의 1일 단백질 요구량인 1.0g/day보다 많은 지구성 운동종목 선수의 경우, 체중 1㎏당 1.2~1.4g/day, 순발력형 운동종목 선수의 경우 체중 1㎏당 1.4~1.8g/day을 권장하고 있다.Athletes' calorie intake is determined by the calorie consumption associated with exercise, and nutrient needs vary with intensity and time of exercise and with the type of exercise. In the case of Korean athletes, the nutritional recommendation (RDA) is 1.5 to 2 times that of the general public, 3,000 to 5,000 kcal / day for male athletes and 2,500 to 3,500 kcal / day for female athletes. For endurance athletes with more than 1.0g / day daily protein requirement, 1.2-1.4g / day per kilogram of body weight and 1.4-1.8g / day per kilogram of body weight for active athletes are recommended. .
운동선수에게 있어서 단백질은 특별히 중요한 영양소 중의 하나로 적절한 양을 섭취해야 한다. 운동 선수들이 일반인들과는 달리 단백질의 소요량이 많은 이유는 운동 중에 단백질이 에너지원으로 이용되게 되는데, 특히 웨이트 트레이닝 시에는 근육단백질의 분해가 왕성해지므로 소모한 근육을 원래의 상태로 보상하고 운동 후 회복기에 단백질 합성이 활발하게 하기 위함이다.Protein is one of the most important nutrients for athletes. The reason why athletes have a high requirement of protein unlike general people is that protein is used as energy source during exercise. Especially during weight training, muscle protein breaks down so that the muscles that are consumed are compensated to their original state. This is to activate the protein synthesis.
상기와 같은 새로운 영양보조식품의 개발의 필요에 따라 본 발명자는, 근육세포의 35%가 루이신(leucine), 이소루이신(isolucine), 발린(valine)으로 이루어져 있으며, 근육의 성장과 발달에 필수적인 분지사슬형 아미노산(branched-chain amino acid, BCAA)은 필수아미노산으로, 체내에서 합성될 수 없기 때문에 음식이나 보충제를 통하여 공급해야 하는 것에 주목하였다. According to the needs of the development of such a new dietary supplement, the present inventors, 35% of the muscle cells are composed of leucine (leucine), isoleucine (isolucine), valine (valine), the muscle growth and development Essential branched-chain amino acids (BCAAs) are essential amino acids, and because they cannot be synthesized in the body, they have to be supplied through food or supplements.
특히, 상기 3가지의 분지사슬형 아미노산은 근육 구성시 필요한 다른 아미노산의 합성을 도우며, 인슐린 생성을 촉진시키고, 다른 아미노산과 다르게 간보다 근육에서 빨리 흡수되어 대사되는 것에 주목하였다.In particular, it is noted that the three branched chain amino acids help the synthesis of other amino acids required for muscle composition, promote insulin production, and are absorbed and metabolized faster in the muscle than the liver, unlike other amino acids.
이에 따라, 본 발명자는 각종 식품에 포함된 필수 아미노산의 조성에 대해 조사하고, 유아, 어린이, 성인별 필수 아미노산의 최소필요량을 조사하므로써, 한국인의 영양권장량에서 제시되는 분지사슬형 아미노산의 1일 필요량보다, 우유, 달걀, 콩, 쇠고기, 밀 등의 식이음식에 포함된 분지사슬형 아미노산이 한국인의 소화흡수 패턴임을 인지하고, 상기 식이음식의 분지사슬형 아미노산의 평균비율에 의한 분지사슬형 아미노산 보충식품을 개발하고자 한다. Accordingly, the present inventors investigated the composition of essential amino acids contained in various foods, and by examining the minimum required amount of essential amino acids for infants, children, and adults, the daily required amount of the branched chain amino acids suggested in the recommended nutritional amount of Koreans Recognizing that the branched chain amino acids contained in dietary foods such as milk, eggs, soybeans, beef, and wheat is a digestive absorption pattern of Koreans, supplementing branched chain amino acids by the average ratio of the branched chain amino acids of the dietary foods To develop food.
상기와 같은 목적을 달성하기 위하여, 혈당량을 감소시키며 상처회복에 영양분으로 사용되는 루이신(L)과, 헤모글로빈 형성에 필요한 이소루이신(I)과, 간과 근육의 당을 에너지로 전환하는 발린(V) 등의 리브(LIV)에 대한 집중적인 조사분석과 실험을 수행하였다.In order to achieve the above object, leucine (L), which is used as a nutrient for wound recovery and blood sugar reduction, isoleucine (I) necessary for hemoglobin formation, and valine, which converts sugars of liver and muscle into energy, Intensive investigation analysis and experiments were performed on the ribs (V) and the like.
단백질 섭취는 근력향상에 꼭 필요하지만 많이 섭취한다고 해서 섭취한 양 모두가 근육합성에 쓰이는 것은 아니다. 필요 이상 섭취할 경우 체내에 저장 할 수 없으므로 결국 에너지원으로 연소시키게 되는데, 아미노산의 아미노기는 체내에서 완전 연소가 되지 않아 체외로 배설되고, 배설과 동시에 칼슘의 배설량도 많아지므로 간과 신장 등의 신진대사에 영향을 미친다. 그러므로 선수들의 단백질 섭취량에 대한 부정적인 효과에 대하여 충족, 보완할 수 있는 방편으로 LIV의 보충이 필요하다.Protein intake is essential for improving muscle strength, but not all of it is used for muscle synthesis. If it is ingested more than necessary, it cannot be stored in the body, so it is eventually burned as an energy source.Amino groups of amino acids are not completely burned in the body and are excreted outside the body, and the amount of calcium excreted increases with metabolism such as liver and kidney. Affects. Therefore, supplementation of LIV is necessary as a way to meet and supplement the negative effects on athletes' protein intake.
리브(LIV)는 근육단백질의 대략 70%로 구성되어 있고 글리코겐처럼 장기간의 강도 있는 운동 중에 소모된다. 운동 중 주로 사용되는 에너지원이 탄수화물로 알려져 있기 때문에 강도 높은 운동을 할 때 근육단백질이 파괴되는 것을 상쇄한다고 알려진 리브(LIV) 보충제가 부각되게 되었다. 그러나 리브(LIV)의 연구에 대해서 정확한 결과를 도출할 만한 실험 프로토콜이 아직 정립되지 않은 이유로 이견이 많은 실정이다. 리브(LIV)의 섭취는 운동 후에 섭취할 경우 근 회복력에 도움을 주는 효과에 관해서는 많은 전문가들이 인정하고 있다.Liv (LIV) consists of approximately 70% of muscle protein and is consumed during prolonged intense exercise, such as glycogen. Because carbohydrates are the main energy source used during exercise, rib supplements (LIV), which are known to offset muscle protein destruction during intense exercise, have emerged. However, disagreements have arisen because experimental protocols have not yet been established to yield accurate results for LIV studies. Ingestion of ribs (LIV) is recognized by many experts as to their effects on muscle recovery after ingestion.
리브(LIV)의 특징 및 주요기능은 다음과 같다.The features and main functions of LIV are as follows.
1. 근육분해 지연 - 근육분해를 막아 준다.1. Delayed muscle breakdown-prevents muscle breakdown.
2. 질소평형 향상2. Improve Nitrogen Equilibrium
3. 에너지 생성 촉진 - 지구력을 요하는 운동에 에너지 생성을 촉진한다.3. Promote energy generation-Promote energy generation in endurance-related movements.
4. 근육생성 증가4. Increase muscle building
5. 근육속의 에너지 생성원료5. Energy generation material in muscle
6. 근육과 에너지 대사를 합리적으로 돕는다.6. Reasonably helps muscle and energy metabolism.
7. 단백질 합성을 보조하고, 단백질의 붕괴를 최소화 한다.7. Assist protein synthesis and minimize protein disruption.
8. 근육조직의 회복, 성장, 발달에 관여한다.8. Involved in the recovery, growth and development of muscle tissue.
9. 운동하는 동안에 쓰이는 골격근육조직의 중요한 열량원이다.9. It is an important calorie source of skeletal muscle tissue used during exercise.
10. 단백질의 합성을 촉진하고 단백질 분해를 억제한다.10. Promote the synthesis of proteins and inhibit protein degradation.
11. 분지사슬아미노산 3종은 언제나 함께 섭취하여야 필요한 기능을 충족한다.11. Three branched chain amino acids should always be taken together to meet the required function.
12. 탄수화물의 이용률을 높여 준다.12. Increase carbohydrate utilization.
13. 근육세포가 근육조직을 형성하도록 도와준다.13. Helps muscle cells form muscle tissue.
14. 근육세포 내에서 단백질의 합성을 촉진시킨다.14. Promote the synthesis of proteins in muscle cells.
15. 근육세포에서 대사 된다.15. Metabolized in muscle cells.
16. 루이신, 이소루이신, 발린이 상호 균형을 이루어야 하다.16. Leucine, isoleucine, and valine should be balanced.
루이신, 이소루이신, 발린은 그 모양이 분지 사슬과 같이 엉겨있다고 해서 분지사슬형 아미노산(Branched Chain Amino Acids)이라 칭하며 그 주요 기능을 달성하기 위해서는 3가지 필수 아미노산의 상호 균형과 배합 비율이 가장 중요하다.Leucine, isoleucine, and valine are called branched chain amino acids because their shape is intertwined like branched chains. It is important.
본 발명에서는 3가지 분지사슬 아미노산의 균형과 조화를 이루기 위하여 자연에서 존재하는 우유, 달걀, 콩, 쇠고기, 밀 등에 존재하는 리브(LIV)를 분석(<표1> 참조)하였으며, 사람의 유아, 어린이, 성인의 필수아미노산 중 리브(LIV)의 최소 필요량(<표2> 참조)을 참고하였다.In the present invention, in order to balance and harmonize three branched chain amino acids, ribs (LIV) present in milk, eggs, soybeans, beef, wheat, etc., which exist in nature, were analyzed (see Table 1). Reference is made to the minimum required amount of LIV in essential amino acids of children and adults (see Table 2).
<표1> 자연에 존재하는 음식물의 LIV함량<Table 1> LIV content of foods in nature
<표2> 사람의 LIV 최소필요량(mg/kg체중/1일)<Table 2> Minimum LIV Required for Humans (mg / kg body weight / day)
<표2>의 성인의 리브(LIV)의 최소 필요량은 인체에서 흡수된 최종 리브(LIV)를 기준으로 한 것이므로, 인체는 보충식품을 경구투여하여 최종적으로 인체에서 흡수하여야 이를 활용할 수 있다는 측면에서 <표1>의 식이음식에 포함된 리브(LIV)의 평균비율에 주목하게 되었으며, 이에 따라 한국인의 식단에 많이 오르는 우유, 달걀, 콩, 쇠고기, 밀 등의 식이음식에 포함된 리브(LIV)가 한국인의 소화흡수 패턴임을 인지하고, 상기 식이음식의 리브(LIV)의 평균비율에 의한 분지사슬형 아미노산 보충식품을 개발하였다.Since the minimum required amount of the adult's rib (LIV) in Table 2 is based on the final rib absorbed by the human body, the human body should be absorbed by the human body by oral supplementation and finally absorbed by the human body. Attention was drawn to the average proportion of ribs (LIV) in the dietary foods of Table 1, and accordingly, ribs (LIVs) included in dietary foods such as milk, eggs, beans, beef, wheat, etc. Recognized that the Korean is a digestive absorption pattern, and developed a branched chain amino acid supplement food by the average ratio of the rib (LIV) of the diet.
본 발명에 의한 분지사슬 아미노산 보충 식품은, 루이신 45중량%와, 이소루이신 25중량%와, 발린 30중량%로 구성된 리브(LIV)를 70%포함하며, 나머지 30%는 L-글루타민 20%, 타우린9%, 기타 각종 비타민과 미네랄이 1%가 함유되어 있다.The branched chain amino acid supplement according to the present invention comprises 70% rib (LIV) composed of 45% by weight of leucine, 25% by weight of isoleucine, and 30% by weight of valine, and the remaining 30% is L-glutamine 20 It contains 1% of taurine, 9% of taurine and other vitamins and minerals.
상기 리브(LIV)는 루이신 40~50중량%와, 이소루이신 20~30중량%와, 발린 25~35중량%로 구성될 수 있다.The rib (LIV) may be composed of 40 to 50% by weight of leucine, 20 to 30% by weight of isoleucine, and 25 to 35% by weight of valine.
루이신은 혈당량을 감소시키고, 상처회복에 영양분으로 사용되며, 이소루이신은 헤모글로빈 형성에 필요하며, 발린은 간과 근육의 당을 에너지로 전환하는 아미노산이다.Leucine is used to reduce blood sugar levels and as a nutrient for wound healing, isoleucine is required for hemoglobin formation, and valine is an amino acid that converts sugars in the liver and muscle into energy.
전체 분지사슬 아미노산 보충 식품은 리브(LIV)는 65~75%를 포함하고, 지나친 운동, 스트레스, 과로일 때 필수적인 L-글루타민은 15~25중량%(상기 LIV의 중량의 20 내지 35%)과, 타우린 5~15%(상기 LIV의 중량의 7 내지 20%)를 포함하며, 항산화물질이며 상기 리브(LIV)의 흡수와 대사를 돕기 위해 필요한 기타 각종 비타민과 미네랄을 2%이하(상기 LIV의 중량의 0.01% 내지 2.9%) 포함한다.The total branched chain amino acid supplement contains 65-75% rib (LIV) and 15-25% L-glutamine (20-35% of the weight of the LIV), which is essential for excessive exercise, stress and overwork. , 5 to 15% of taurine (7 to 20% of the weight of the LIV), is an antioxidant and various other vitamins and minerals required to help the absorption and metabolism of the rib (LIV) 2% or less (the LIV of 0.01% to 2.9% of the weight).
L-글루타민은 근육의 단백질합성을 촉진시키며, 근손실을 예방하고, 근육의 회복 속도를 빠르게 하며, 빠른 근육 성장에 도움을 주며, 체내 풍부한 유리 아미노산으로 전체 아미노산의 60%를 차지하고 있으며, 다른 아미노산에 의해 체내에서 합성되기는 하지만, 신체가 훈련과 운동 등으로 스트레스하에 있을 때 근육에 있는 글루타민이 급속히 이용되므로 운동선수에게 있어서 근육의 유지와 체력저하를 막기 위하여 반드시 섭취하여야 하는 선택적 필수아미노산이다.L-Glutamine promotes protein synthesis in muscles, prevents muscle loss, speeds up muscle recovery, helps fast muscle growth, and is a rich free amino acid in the body that makes up 60% of the total amino acids. Although it is synthesized by the body, glutamine in muscles is rapidly used when the body is under stress by training and exercise, and thus it is an essential essential amino acid which must be ingested in athletes to prevent muscle maintenance and stamina.
타우린(taurine)은 아미노산처럼 양성 전해질(電解質)의 성질을 갖고 있는 아미노에틸술폰산으로, 타우린의 주된 생리 작용은 담즙 생성, 콜레스테롤 농도 조절, 이온의 세포막 투과성 조절, 항산화 작용, 과도한 신경 흥분 억제 등이다. 체액보다는 심장과 골격근, 뇌, 생식 기관의 세포에 들어 있다. 타우린은 심장의 칼슘 이온 농도가 정상보다 낮을 때 심장의 수축력을 약화시키므로 강심제로 알려져 왔다. 또 담즙산과 중합체를 형성하여 답즙산의 독성을 완화하고 장에서 지방 흡수를 돕는다. 타우린은 세포막에서 과산화물과 질소 산화물, 유리기가 세포막에 손상을 주기 전에 제거함으로써 세포를 보호한다. 타우린은 뇌에 들어 있는 아미노산 중 농도가 가장 높으며, 신경이 지속적으로 흥분될 때 과도한 신경 흥분을 억제하여 신경 안정 효과도 있어 운동에 의한 스트레스를 감소시켜준다.Taurine is an aminoethylsulfonic acid that has the properties of a positive electrolyte like amino acids. The main physiological functions of taurine are bile formation, cholesterol concentration control, ionic cell membrane permeability, antioxidant activity, and excessive nervous excitability. . They are found in cells of the heart, skeletal muscle, brain, and reproductive organs rather than body fluids. Taurine has been known as a cardiovascular drug because it weakens the contractile force of the heart when the heart's calcium ion concentration is lower than normal. It also forms bile acids and polymers to mitigate the toxicity of bile acids and help the intestines absorb fat. Taurine protects cells by removing peroxides, nitrogen oxides, and free radicals from cell membranes before they damage the cell membranes. Taurine has the highest concentration of amino acids in the brain and, when the nerves are constantly excited, suppresses excessive nerve excitement and has a nerve stabilizing effect, reducing stress caused by exercise.
이러한 지나친 운동, 스트레스, 과로일 때 필수적인 L-글루타민과 타우린을 LIV에 첨가하여 분지사슬 아미노산 보충 식품의 기능을 향상시켰다.L-glutamine and taurine, which are essential for excessive exercise, stress and overwork, have been added to LIV to enhance the function of branched chain amino acid supplements.
분지사슬 아미노산 보충 식품에는 상기 엘-글루타민이 상기 리브(LIV)의 중량의 20 내지 35% 포함되었으며, 타우린은 상기 리브(LIV)의 중량의 7 내지 20%가 포함되었다.Branched-chain amino acid supplements contained 20-35% of the weight of the rib (LIV) in the L-glutamine and 7-20% of the weight of the rib (LIV) in the taurine.
운동선수는 항산화 영양소를 적절히 섭취해야하는데, 항산화 영양소에는 비타민 C, E, β-carotine 등이 있으며, 대표적인 비타민 C는 결합조직의 콜라겐(collagen 근섬유단백질) 합성에 중요하며, 에너지 대사계인 사이토크롬(cytochrome)류를 구성하는 미네랄과 철분의 소화, 흡수를 돕는다. 또한 스트레스에 반응할 때 분비되는 물질인 히스타민 제거작용을 하여 계속되는 시합으로 지친 선수들의 컨디션을 조절하는데 중요한 역할을 한다.Athletes need to take proper antioxidant nutrients, which include vitamins C, E, and β-carotine. Representative vitamin C is important for the synthesis of collagen (collagen myofoprotein) in connective tissues, and is an energy metabolic cytochrome ( It helps digestion and absorption of minerals and iron that make up cytochromes. In addition, histamine elimination, a substance secreted in response to stress, plays an important role in regulating the condition of exhausted athletes due to continued competition.
인체의 생체활동 중에 생성되는 부산물인 활성산소는 체내의 에너지 생성, 지질이나 단백질의 대사과정, 카테콜아민 반응 그리고 각종 염증성 반응에서 정상적으로 발생되나, 대부분 항산화제에 의하여 중화된다. 또한 여러 질병 즉 고혈압, 동맥경화, 관상동맥질환 등의 심혈관계 질환, 악성종양, 만성 염증성 질환, 파킨슨씨 증후군, 간질, 각종 뇌손상, 백내장, 피부암, 자가면역질환 등의 발생원인으로 라디칼, 과산화물이 매우 중요한 역할을 하고 있는 것으로 알려져 있다.Free radicals, which are by-products produced by the body's biological activities, normally occur in energy production in the body, metabolism of lipids or proteins, catecholamine reactions, and various inflammatory reactions, but are mostly neutralized by antioxidants. In addition, cardiovascular diseases such as hypertension, arteriosclerosis, and coronary artery disease, malignant tumors, chronic inflammatory diseases, Parkinson's syndrome, epilepsy, various brain injuries, cataracts, skin cancers, autoimmune diseases, etc. This is known to play a very important role.
운동을 하는 동안 인체에서는 산소 요구량이 급속히 늘어나게 된다. 활동하는 근육에서 많은 산소가 소비되면서 많은 활성산소가 생성되고 이것이 세포막 구조를 손상시키기 때문에 연구자들은 이러한 손상에 대해서 운동 직후 산화과정의 증가된 생성물과 관계된 것으로 규명하고 있다.During exercise, the body's oxygen demand increases rapidly. Because a lot of oxygen is consumed in active muscles, many free radicals are produced, which damage cell membrane structures, and the researchers found that these damages are related to increased products of the oxidation process immediately after exercise.
운동선수가 스트레스를 많이 받는 상태에서 장시간 운동을 지속함으로 발생된 활성산소는 세포막의 유동성, 투과성 그리고 흥분성의 변화나 세포막에 붙어 있는 효소들의 작용을 변화시키는 결과를 초래한다. 일반적으로 활성산소에 의해 산화적 스트레스를 받는 것은 몸을 구성하는 모든 세포라고 할 수 있는데 그 중 대표적인 것이 지질, 단백질, DNA, 핵산, 효소 등이며, 이들이 산화적 손상을 받으면 세포의 기능이 저하된다. 또한 격렬한 운동은 평균 근육 산소 요구량의 20배 이상 요구하므로, 갑자기 상승된 산소 요구량은 저산소증 및 젖산축적 등을 유발하여 근육의 피로를 유발시킨다.Free radicals generated by athletes under stress under prolonged exercise may result in changes in cell membrane fluidity, permeability and excitability, or in the action of enzymes attached to the cell membrane. In general, oxidative stress caused by free radicals can be said to be all the cells that make up the body, and the representative ones are lipids, proteins, DNA, nucleic acids, and enzymes. . In addition, strenuous exercise requires more than 20 times the average muscle oxygen demand, so the suddenly increased oxygen demand causes hypoxia and lactic acid accumulation, leading to muscle fatigue.
격렬한 운동은 활성산소를 증가시켜 이것이 세포를 파괴하며 노화를 촉진하지만 이는 항산화제(antioxidant nutrients)에 의해 중화되며 운동의 종류와 강도, 시간 등의 조절로 더 큰 효과를 가져올 수 있다.Intense exercise increases free radicals, which destroy cells and promote aging, but they are neutralized by antioxidant nutrients and can have greater effects by controlling the type, intensity and time of exercise.
상기와 같은 항산화작용을 하고 상기 리브(LIV)의 흡수와 대사를 돕기 위해 필요한 비타민 9종과 미네랄 5종을 첨가 하였다. 상기 비타민과 미네랄은 비타민A, 비타민C, 비타민B1염산염, 비타민B2, 비타민B6염산염, 비타민B12, 비타민D3, 엽산, 니코틴산아미드, 인산칼슘, 철, 산화마그네슘, 산화아연, 말토덱스트린등이다.To the antioxidant activity as described above and to support the absorption and metabolism of the rib (LIV) was added to nine vitamins and five minerals. The vitamins and minerals are vitamin A, vitamin C, vitamin B1 hydrochloride, vitamin B2, vitamin B6 hydrochloride, vitamin B12, vitamin D3, folic acid, nicotinamide, calcium phosphate, iron, magnesium oxide, zinc oxide, maltodextrin and the like.
상기와 같은, 분지사슬 아미노산 보충식품의 효능을 확인하기 위하여 K대학과 Y대학에서 태권도 선수로 활동하고 있는 남자선수 48명을 대상으로 LIV섭취량에 따라 각각 16명씩 3군 즉, placevo group(LIV 0g/day 투여, PSG로 표기), half supplemented group(LIV 2.5g/day 투여, HSG로 표기), full supplemented group(LIV 5.0g/day 투여, FSG로 표기)로 나누어 12주간 구강섭취시켰다.In order to confirm the efficacy of the branched chain amino acid supplements as described above, 48 male athletes who are active as taekwondo athletes at K and Y colleges were selected from three groups, namely placevo group (LIV 0g, 16 persons each according to LIV intake). / day administration, PSG), half supplemented group (LIV 2.5g / day administration, HSG), full supplemented group (LIV 5.0g / day administration, FSG) was divided into oral intake for 12 weeks.
공급한 리브(LIV)는 1캡슐당 70%의 리브(LIV)가 함유되어 있는 보충용식품으로 이소루이신, 루이신, 발린의 구성비율은 1:1.8:1.2였다.The supplied ribs (LIV) were supplements containing 70% of the ribs (LIV) per capsule. The composition ratio of isoleucine, leucine, and valine was 1: 1.8: 1.2.
운동선수를 위한 리브(LIV)의 권장량은 아직 제시된 바가 없으므로, 일반인 1일 권장량의 2배를 1일공급량(5.0g)으로 하였으며, 운동 직전과 직후에 섭취하도록 하였다.Since the recommended amount of ribs for athletes has not been suggested yet, the daily supply (5.0 g) was twice the daily recommended amount for the general public, and was taken immediately before and after exercise.
연구기간은 동계 합숙 훈련이 시작되는 시점인 2002년 1월 7일 ~ 2002년 3월 30일 까지 였으며, 훈련은 평균적으로 주중에는 새벽운동(6:00~7:00, 산책 및 구보), 오전운동 (10:00~12:00), 오후운동(15:00~17:30), 야간운동(19:30~21:00)으로 나누어 실시하였으며, 토요일은 오전운동만을 실시, 일요일은 개별적으로 실시하였다.The study period ranged from January 7, 2002 to March 30, 2002, at the beginning of the winter camp training. It was divided into exercise (10: 00 ~ 12: 00), afternoon exercise (15: 00 ~ 17: 30), and night exercise (19: 30 ~ 21: 00). On Saturdays, only morning exercise was performed. Was carried out.
혈중 아미노산 함량(Serum level of amino acids)Serum level of amino acids
혈중 아미노산 함량에 대한 그래프는 도1 및 도2와 같다.Graphs of the amino acid content in blood are shown in FIGS. 1 and 2.
도1은 필수 아미노산에 대한 것이며, 도2는 비필수 아미노산에 대한 것이다.Figure 1 is for essential amino acids and Figure 2 is for non-essential amino acids.
혈액 분석 결과, 이소루이신은 보충후 모든 군에서 유의하게 증가하였으며, 루이신과 발린은 HSG와 FSG에서만 증가하였다. Blood analysis showed that isoleucine was significantly increased in all groups after supplementation, and leucine and valine were only increased in HSG and FSG.
필수 아미노산인 히스티딘은 PSG와 HSG에서 보충후에 유의하게 감소하였으나, FSG에서는 유의하게 증가하였다. 라이신, 메티오닌, 페닐알라닌은 보충후에 모든 군에서 유의하게 증가하였고, 트레오닌은 HSG와 FSG에서 유의하게 증가하였다.Histidine, an essential amino acid, decreased significantly after supplementation in PSG and HSG, but significantly increased in FSG. Lysine, methionine and phenylalanine were significantly increased in all groups after supplementation, and threonine was significantly increased in HSG and FSG.
비필수 아미노산에서는, 알라닌, 글리신, 타이로신은 HSG와 FSG에서 유의하게 증가하였으며, 아르기닌, 세린은 FSG에서만 유의하게 증가하였고, 아스파르트산, 글루타민은 보충후에 모든 군에서 유의하게 증가하였다.In non-essential amino acids, alanine, glycine and tyrosine were significantly increased in HSG and FSG, arginine and serine were significantly increased only in FSG, and aspartic acid and glutamine were significantly increased in all groups after supplementation.
최대 무산소 파워(Maximum anaerobic power)Maximum anaerobic power
최대 무산소 파워에 대한 조사결과는 <표3>과 같다.The results of the investigation on the maximum oxygen free power are shown in Table 3.
보충전 PSG가 1,318.1±159.9watt, HSG와 FSG가 각각 1,402.1±177.9watt, 1,346.9±150.0watt로 세 군간의 차이는 관찰되지 않았으나, 보충 12주째에는 PSG가 1,300.3±130.3watt, HSG와 FSG가 각각 1,401.1±239.2watt, 1,445.4±161.3watt로 FSG에서 유의하게(P<0.05) 높았다. 또한 FSG에서 보충전보다 보충후에 유의하게 증가하였다(P<0.01).PSG was 1,318.1 ± 159.9watts before supplementation, HSG and FSG were 1,402.1 ± 177.9watts and 1,346.9 ± 150.0watt, respectively, but there were no differences between the three groups, but at 12 weeks of supplementation, PSG was 1,300.3 ± 130.3watts and HSG and FSG were 1,401.1 ± 239.2watts and 1,445.4 ± 161.3watts were significantly higher in FSG (P <0.05). FSG significantly increased after supplementation than before supplementation (P <0.01).
파워를 체중으로 나눈 결과는, 보충전 PSG가 17.9±2.1watt/kg, HSG와 FSG가 각각 18.8±2.3watt/kg, 18.7±1.6watt/kg로 세 군간의 차이는 관찰되지 않았으나, 보충 12주째에는 PSG가 17.5±12.7watt/kg, HSG와 FSG가 각각 18.7±1.8watt/kg, 20.4±2.3watt/kg로 FSG에서 유의하게(P<0.05) 높았다. 또한 FSG에서 보충전보다 보충후에 유의하게 증가하였다(P<0.01).The results of power divided by body weight were 17.9 ± 2.1watt / kg before supplementation, 18.8 ± 2.3watt / kg and 18.7 ± 1.6watt / kg for HSG and FSG, respectively. The PSG was 17.5 ± 12.7watt / kg, HSG and FSG were 18.7 ± 1.8watt / kg and 20.4 ± 2.3watt / kg, respectively (P <0.05). FSG significantly increased after supplementation than before supplementation (P <0.01).
<표3> 그룹별 최대 무산소 파워의 비교<Table 3> Comparison of maximum oxygen free power by group
따라서, 리브(LIV)를 5.0g/day 투여한 그룹(FSG)에서는 루이신, 이소루이신, 발린뿐만 아니라 다른 아미노산들도 유의하게 증가하여 최대 무산소 파워를 향상시키는 것으로 판단된다.Therefore, in the group (FSG) administered 5.0 g / day of the rib (LIV), it is determined that not only leucine, isoleucine, valine but also other amino acids are significantly increased to improve the maximum anaerobic power.
이상과 같이 본 발명에 의한 분지사슬 아미노산 보충 식품을 태권도선수, 골프선수, 격투기선수, 축구선수, 야구선수, 유도선수, 레슬링선수, 배구선수, 농구선수, 축구선수 등의 운동선수들에게 섭취시키므로써, 선수들의 혈중 필수아미노산의 농도를 상승시키며, 근 글리코겐의 분해를 감소시켜 근력의 감소를 억제하는 효과가 있다.As described above, the branched chain amino acid supplement food according to the present invention is ingested to athletes such as taekwondo players, golf players, martial arts players, soccer players, baseball players, judo players, wrestlers, volleyball players, basketball players, and soccer players. In addition, it increases the concentration of essential amino acids in the blood of athletes, and reduces the breakdown of muscle glycogen has the effect of suppressing the decrease in muscle strength.
또한, 무기적 상태에서 최대의 근파워의 증대를 기대 할수 있으므로 골프, 태권도, 격투기등 개인 종목 레저 및 전문 운동선수의 경기력을 향상시켜주는 건강기능식품으로 활용될 수 있으며, 일반인들에게는 육체적인 노동의 강도에 대한 적응력을 증대시키고, 선수들에게는 훈련향을 증가시켜줌으로 노동의 질을 높이고, 운동량의 질적 수준을 향상시켜주는 건강기능식품으로 활용될 수 있으며, 혈당의 감소에 영향을 미치고 근육내의 아미노산의 양을 증대시킴으로 당뇨병환자를 위한 과학적인 영양제로서의 건강기능식품으로 활용될 수 있으며, 육체피로로 인한 여러 장애를 극복할수 있는 건강기능식품으로의 활용이 기대된다. In addition, it can be used as a health functional food to improve the performance of individual sports such as golf, taekwondo, martial arts, and professional athletes. It can be used as a health functional food to increase the adaptability to strength, increase the training incentives for athletes, improve the quality of labor and improve the quality of exercise, affect the reduction of blood sugar and amino acid in muscle Increasing the amount of nutrients can be used as a dietary supplement as a scientific nutritional supplement for diabetics, and is expected to be used as a dietary supplement that can overcome various obstacles caused by physical fatigue.
도1은 본 발명에 따른 연구에서 실험군별 필수 아미노산의 혈중 농도그래프.1 is a graph of blood concentrations of essential amino acids for each experimental group in a study according to the present invention.
도2는 본 발명에 따른 연구에서 실험군별 비필수 아미노산의 혈중 농도그래프.Figure 2 is a graph of the blood concentration of non-essential amino acids for each experimental group in the study according to the present invention.
Claims (5)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040103923A KR100549697B1 (en) | 2004-12-10 | 2004-12-10 | Amino acid supplement food |
PCT/KR2005/000517 WO2006062273A1 (en) | 2004-12-10 | 2005-02-25 | Branched-amino acid supplement food |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040103923A KR100549697B1 (en) | 2004-12-10 | 2004-12-10 | Amino acid supplement food |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050034568A true KR20050034568A (en) | 2005-04-14 |
KR100549697B1 KR100549697B1 (en) | 2006-02-07 |
Family
ID=36578072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040103923A KR100549697B1 (en) | 2004-12-10 | 2004-12-10 | Amino acid supplement food |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100549697B1 (en) |
WO (1) | WO2006062273A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8962678B2 (en) | 2006-07-05 | 2015-02-24 | Kao Corporation | Senescence inhibitor |
CN112868956A (en) * | 2021-01-27 | 2021-06-01 | 中央民族大学 | Multifunctional sports beverage and preparation method thereof |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011045810A1 (en) | 2009-08-13 | 2011-04-21 | Zota Health Care Limited | Pharmaceutical compositions containing taurine and race-methionine for the treatment of alcoholism |
WO2012005568A1 (en) | 2010-07-07 | 2012-01-12 | N.V. Nutricia | Nutritional composition for the stimulation of muscle protein synthesis |
WO2013124860A1 (en) | 2012-02-23 | 2013-08-29 | Zota Health Care Ltd | Potent revital formulation |
CN112931879A (en) | 2013-06-10 | 2021-06-11 | N·V·努特里奇亚 | Muscle maintenance during weight loss programs in overweight or obese adults |
WO2015177805A1 (en) | 2014-05-19 | 2015-11-26 | Zota Health Care Ltd | Combination of taurine and racemethionine for treatment of liver diseases |
US20220233651A1 (en) * | 2019-06-03 | 2022-07-28 | Société des Produits Nestlé S.A. | Recover dietary supplement |
CN111296843A (en) * | 2020-03-03 | 2020-06-19 | 上海泓商生物科技有限公司 | Anti-fatigue and sports probiotics |
CN113080463A (en) * | 2021-04-23 | 2021-07-09 | 江苏金维氨生物工程有限公司 | Powder for quickly supplementing physical ability |
CN113475661A (en) * | 2021-07-07 | 2021-10-08 | 攀枝花学院 | Multifunctional body-building instant solid beverage and preparation method thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0949764A (en) * | 1995-08-08 | 1997-02-18 | Toshiba Corp | Non-destructive inspection method of injection mold insulating material |
KR100463414B1 (en) * | 2001-08-09 | 2004-12-23 | 주식회사 파시코 | Food-supplement for sports nutrition |
-
2004
- 2004-12-10 KR KR1020040103923A patent/KR100549697B1/en not_active IP Right Cessation
-
2005
- 2005-02-25 WO PCT/KR2005/000517 patent/WO2006062273A1/en active Application Filing
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8962678B2 (en) | 2006-07-05 | 2015-02-24 | Kao Corporation | Senescence inhibitor |
CN112868956A (en) * | 2021-01-27 | 2021-06-01 | 中央民族大学 | Multifunctional sports beverage and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
KR100549697B1 (en) | 2006-02-07 |
WO2006062273A1 (en) | 2006-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jäger et al. | International society of sports nutrition position stand: protein and exercise | |
US8168241B2 (en) | Performance-enhancing dietary supplement | |
ES2249269T3 (en) | SPORTS DRINK THAT INCLUDES VIABLE MICRONUTRIENTS AND LACTOBACILOS. | |
CA2487588C (en) | Drink composition and a method for composing a drink | |
US20080233245A1 (en) | Liquid nutrient composition for improving performance | |
EP2996487B1 (en) | Rice protein supplements | |
WO2006062273A1 (en) | Branched-amino acid supplement food | |
US20030143311A1 (en) | Recovery drink formula and method | |
JP5798648B2 (en) | Anti-fatigue agent containing amino acid composition | |
CN108651998A (en) | It is a kind of have relieve fatigue PURE WHEY of function and preparation method thereof | |
US7740878B2 (en) | Use of betaine to enhance exercise performance | |
WO2011096413A1 (en) | Agent for improving motility function | |
Ali et al. | Sports and exercise supplements | |
US20030104107A1 (en) | Energy drink formula and method | |
US20050013884A1 (en) | Compositions and methods for treating heart disease | |
KR100463414B1 (en) | Food-supplement for sports nutrition | |
CN110801018A (en) | Coenzyme Q10Vitamin C sports buccal tablet | |
RU2609813C1 (en) | Functional food product "amino jam" | |
US20120282232A1 (en) | Nutrient Hydration Bar | |
EP3984378A1 (en) | Dietary supplement for sport use | |
CN102172287B (en) | Alkaline food containing abundant potassium and magnesium | |
Pasin et al. | US Whey products and sports nutrition | |
RU2579211C1 (en) | Dry mixture for making sports beverage | |
Chapman et al. | Nutritional supplements to reduce muscle damage and enhance athlete recovery | |
Burke | Branched-chain amino acids (BCAAs) and athletic performance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
G15R | Request for early opening | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20100121 Year of fee payment: 5 |
|
LAPS | Lapse due to unpaid annual fee |